

# WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Friday, October 15, 2004

[Hide?](#) [Set Name](#) [Query](#)

[Hit Count](#)

*DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ*

<input type="checkbox"/>	L9	L7 AND L8	47
<input type="checkbox"/>	L8	L1 AND L4	466
<input type="checkbox"/>	L7	angina OR myocardial ischemia OR myocardial infarct	26573
<input type="checkbox"/>	L6	L5 AND L4	29
<input type="checkbox"/>	L5	L1 AND L2	119
<input type="checkbox"/>	L4	FGF-1 OR FGF-2 OR bFGF OR aFGF OR VEGF	12449
<input type="checkbox"/>	L3	growth factor OR FGF-1 OR FGF-2 OR bFGF OR aFGF OR VEGF	65749
<input type="checkbox"/>	L2	coronary artery disease	7961
<input type="checkbox"/>	L1	(514/2.CCLS.)	6335

END OF SEARCH HISTORY

# Hit List

[Clear](#) | [Generate Collection](#) | [Print](#) | [Fwd Refs](#) | [Bkwd Refs](#) | [Generate OACS](#)

## Search Results - Record(s) 1 through 29 of 29 returned.

1. Document ID: US 20040097401 A1

**Using default format because multiple data bases are involved.**

L6: Entry 1 of 29

File: PGPB

May 20, 2004

PGPUB-DOCUMENT-NUMBER: 20040097401

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040097401 A1

TITLE: Lysine in therapeutic angiogenesis, particularly in treating ischaemic conditions

PUBLICATION-DATE: May 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Datta, Debatosh	Kolkata		IN	

US-CL-CURRENT: 514/2; 514/564, 514/565

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KWMC](#) | [Drawn Des.](#)

2. Document ID: US 20040033971 A1

L6: Entry 2 of 29

File: PGPB

Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040033971

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040033971 A1

TITLE: Polypeptides and nucleic acids encoding same

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gangolli, Esha A.	Madison	CT	US	
Patturajan, Meera	Branford	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Kekuda, Ramesh	Norwalk	CT	US	
Stone, David J.	Guilford	CT	US	
Anderson, David	Branford	CT	US	
Shimkets, Richard A.	Guilford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	

Zerhusen, Bryan D.	Branford	CT	US
Liu, Xiaohong	Branford	CT	US
Spytek, Kimberly A.	New Haven	CT	US
Casman, Stacie J.	North Haven	CT	US
Boldog, Ference L.	North Haven	CT	US
Smithson, Glennda	Guilford	CT	US
Li, Li	Branford	CT	US
Ji, Weizhen	Branford	CT	US
MacDougall, John R.	Hamden	CT	US

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/7.1, 514/2, 530/387.1, 536/23.1

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention farther discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [EPOC](#) | [Drawn Desc](#)

3. Document ID: US 20030229003 A1

L6: Entry 3 of 29

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229003

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229003 A1

TITLE: Use of transcription factors for treating inflammation and other diseases

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Oettgen, Peter	Brookline	MA	US	
Libermann, Towia	Newton	MA	US	
Goldring, Mary	Auburndale	MA	US	

US-CL-CURRENT: 514/1; 435/4, 435/6, 514/2, 514/44, 514/54

ABSTRACT:

The present invention provides a method of treating inflammation in a mammal comprising altering the activity of a transcription factor involved in the inflammatory response. The invention also relates to the use of transcription factors to screen compounds that are capable of reducing inflammation. The invention also relates to the use of transcription factors in methods of diagnosing the presence of an inflammatory disease in a tissue of a mammal and methods of monitoring the treatment of an inflammatory disease in a tissue of a mammal.

4. Document ID: US 20030215840 A1

L6: Entry 4 of 29

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215840

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030215840 A1

TITLE: Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas J.	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	
Galvin, Katherine M.	Jamaica Plain	MA	US	
Healy, Aileen	Medford	MA	US	
Acton, Susan L.	Lexington	MA	US	
Donoghue, Mary A.	West Roxbury	MA	US	
Stagliano, Nancy	North Reading	MA	US	
Perodin, Jacqueline	Arlington	MA	US	
Rodrigue-Way, Amelie	Malden	MA	US	

US-CL-CURRENT: 435/6; 424/146.1, 435/7.2, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 and 6585 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

5. Document ID: US 20030199425 A1

L6: Entry 5 of 29

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199425

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030199425 A1

TITLE: Compositions and methods for treatment of hyperplasia

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Desai, Neil P.	Los Angeles	CA	US	
Soon-Shiong, Patrick	Los Angeles	CA	US	

US-CL-CURRENT: 514/2; 424/45, 514/291, 514/365, 514/449

ABSTRACT:

In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent.

6. Document ID: US 20030152574 A1

L6: Entry 6 of 29

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152574

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030152574 A1

TITLE: Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas Joseph	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	

US-CL-CURRENT: 424/146.1; 435/7.2, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1419, 58765 or 2210 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Drawn Des](#)

7. Document ID: US 20030104977 A1

L6: Entry 7 of 29

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104977

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030104977 A1

TITLE: METHODS FOR INDUCING ANGIOGENESIS USING MORPHOGENIC PROTEINS AND STIMULATORY FACTORS

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
RIPAMONTI, UGO	SANDTON		ZA	
RAMOSHEBI, LENTSHA NATHANIEL	JOHANNESBURG		ZA	

US-CL-CURRENT: 514/2

ABSTRACT:

The present invention provides a method for inducing angiogenesis at a target locus in a mammal using morphogenic proteins. In addition, this invention also features a method for improving the angiogenic capability of a morphogenic protein at a target locus in a mammal. In this method, the morphogenic protein is capable of inducing angiogenesis when accessible to a progenitor cell in the mammal, and the morphogenic protein stimulatory factor enhances that capability. The morphogenic protein and morphogenic protein stimulatory factor can be administered simultaneously to the target locus. Alternatively, the two components are administered separately, in any order.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Drawn Des](#)

8. Document ID: US 20030083231 A1

L6: Entry 8 of 29

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030083231  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20030083231 A1

TITLE: Blood cell deficiency treatment method

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ahlem, Clarence N.	San Diego	CA	US	
Reading, Christopher	San Diego	CA	US	
Frincke, James	San Diego	CA	US	
Stickney, Dwight	Granite Bay	CA	US	
Lardy, Henry A.	Madison	WI	US	
Marwah, Padma	Middleton	WI	US	
Marwah, Ashok	Middleton	WI	US	
Prendergast, Patrick T.	Straffan		IE	

US-CL-CURRENT: 514/2; 514/169, 514/173, 514/26, 514/44, 514/63

ABSTRACT:

The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn Desc](#)

9. Document ID: US 20020131959 A1

L6: Entry 9 of 29

File: PGPB

Sep 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020131959  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20020131959 A1

TITLE: Means and methods for the modulation of arteriogenesis

PUBLICATION-DATE: September 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Buschmann, Ivo	Freiburg		DE	
Van Royen, Niels	Gundelfingen		DE	
Hofer, Imo	March		DE	

US-CL-CURRENT: 424/93.21; 424/85.1, 424/85.2, 514/2, 514/44

**ABSTRACT:**

The present invention relates generally to the modulation of arteriogenesis and/or the growth of collateral arteries or other arteries from preexisting arteriolar connections. In particular, the present invention provides a method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting an organ, tissue or cells with transforming growth factor beta 1 (TGF.beta.1) or a nucleic acid molecule encoding TGF.beta.1. The present invention also relates to the use of TGF.beta.1 or a nucleic acid molecule encoding TGF.beta.1 for the preparation of pharmaceutical compositions for enhancing arteriogenesis and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Furthermore, the present invention relates to a method for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF.beta.1. The present invention further involves the use of an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF.beta.1 for the preparation of pharmaceutical compositions for the treatment of tumors.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [EPOC](#) | [Draw. Des.](#)

10. Document ID: US 20020061521 A1

L6: Entry 10 of 29

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061521

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061521 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

**ABSTRACT:**

The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for

diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [RMDC](#) | [Drawn Desg](#)

---

11. Document ID: US 20020061294 A1

L6: Entry 11 of 29

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061294

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061294 A1

TITLE: MONONUCLEAR PHAGOCYTES IN THERAPEUTIC DRUG DELIVERY

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LEWIS, CLAIRE E.	SHEFFIELD		GB	
HARRIS, ADRIAN L.	OXFORD		GB	
MARSHALL, JULIAN M	OXFORD		GB	

US-CL-CURRENT: 424/93.21; 424/450, 435/320.1, 435/325, 435/69.1, 514/2, 514/44

ABSTRACT:

The invention relates to the exploitation of the migratory behaviour of mononuclear phagocytes with a view to targeting therapeutic drug delivery. The invention therefore concerns the attachment or incorporation of a therapeutic agent to or into a mononuclear phagocyte and the subsequent migration of the munonuclear phagocyte to a target area.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [RMDC](#) | [Drawn Desg](#)

---

12. Document ID: US 20020058612 A1

L6: Entry 12 of 29

File: PGPB

May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058612

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

**INVENTOR-INFORMATION:**

NAME Franco, Wayne P.	CITY Rocky Hill	STATE CT	COUNTRY US	RULE-47
--------------------------	--------------------	-------------	---------------	---------

US-CL-CURRENT: 514/2; 424/43**ABSTRACT:**

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIPO	Drawn Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

---

 13. Document ID: US 20020037832 A1

L6: Entry 13 of 29

File: PGPB

Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037832

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020037832 A1

TITLE: Use of alpha-MSH and EPO for preventing or treating ischemic conditions

PUBLICATION-DATE: March 28, 2002

**INVENTOR-INFORMATION:**

NAME Nielsen, Soren	CITY Abyhoj	STATE DK	COUNTRY DK	RULE-47
Frokiaer, Jorgen	Abyhoj	DK	DK	
Jonassen, Thomas Engelbrecht Norkild	Frederiksberg	DK	DK	
Bjerke, Thorbjorn	Fredensborg	DK	DK	

US-CL-CURRENT: 514/2; 514/169**ABSTRACT:**

Alpha--melanocyte stimulating hormone (.alpha.-MSH) or an equivalent is used, in conjunction with erythropoietin (EPO) or equivalent, to prevent or treat ischemic conditions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIPO	Drawn Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

---

 14. Document ID: US 20020006895 A1

L6: Entry 14 of 29

File: PGPB

Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006895

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006895 A1

TITLE: Method of treatment of cardiovascular injuries

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moulton, Karen S.	Weston	MA	US	
Folkman, Judah	Brookline	MA	US	

US-CL-CURRENT: 514/2; 424/85.6, 424/85.7, 514/326, 514/475

ABSTRACT:

The present invention provides a method for treating cardiovascular ailments. The method involves first screening an individual to determine their risk of having the potential for unstable plaques. Such individuals can be selected by looking at one of the following criteria: (i) increased plaque neovascularization, (ii) area ratio of intima to wall area of a plaque, (iii) evidence of plaque hemorrhage, or (iv) inflammatory cells associated with plaque vessels. Looking at these criteria permits one to select individuals having the potential for unstable plaques. The method then involves treating the selected individual with an effective amount of an angiogenesis inhibitor.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KOMC](#) | [Draw. Desc](#)

---

15. Document ID: US 6759386 B2

L6: Entry 15 of 29

File: USPT

Jul 6, 2004

US-PAT-NO: 6759386

DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Rocky Hill	CT	06067	

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 4

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Search](#) | [Print](#) | [Claims](#) | [HTMLC](#) | [Drawn Desc](#)

16. Document ID: US 6737404 B2

L6: Entry 16 of 29

File: USPT

May 18, 2004

US-PAT-NO: 6737404

DOCUMENT-IDENTIFIER: US 6737404 B2

TITLE: Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137

DATE-ISSUED: May 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Springer; Barry A.	Wilmington	DE		
Pantoliano; Michael W.	Boxford	PA		
Sharp; Celia M.	Doylestown	PA		

US-CL-CURRENT: 514/12; 514/2, 530/399

ABSTRACT:

The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.

30 Claims, 2 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 2

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Search](#) | [Print](#) | [Claims](#) | [HTMLC](#) | [Drawn Desc](#)

17. Document ID: US 6605592 B2

L6: Entry 17 of 29

File: USPT

Aug 12, 2003

US-PAT-NO: 6605592

DOCUMENT-IDENTIFIER: US 6605592 B2

TITLE: Protein HOFNF53

DATE-ISSUED: August 12, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Baker; Kevin P.	Darnestown	MD		
Birse; Charles E.	North Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Fiscella; Michele	Bethesda	MD		
Komatsoulis; George A.	Silver Spring	MD		
LaFleur; David W.	Washington	DC		
Moore; Paul A.	Germantown	MD		
Olsen; Henrik S.	Gaithersburg	MD		
Rosen; Craig A.	Laytonsville	MD		
Ruben; Steven M.	Olney	MD		
Soppet; Daniel R.	Centreville	VA		
Young; Paul E.	Gaithersburg	MD		
Wei; Ping	Brookeville	MD		
Florence; Kimberly A.	Rockville	MD		

US-CL-CURRENT: 514/2; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1,  
435/71.1, 435/71.2, 514/12, 514/8, 530/350

## ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. In particular, the present application relates to a novel human protein, Protein HOFNF53. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

19 Claims, 22 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 22

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [RIOOC](#) | [Draw Desc](#)

18. Document ID: US 6592862 B1

L6: Entry 18 of 29

File: USPT

Jul 15, 2003

US-PAT-NO: 6592862

DOCUMENT-IDENTIFIER: US 6592862 B1

TITLE: Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections

DATE-ISSUED: July 15, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schaper; Wolfgang	Bad Nauheim/Rodgen			DE
Ito; Wulf D.	Luneburg			DE

## ABSTRACT:

Described is the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting tissue or cells with a monocyte chemotactic protein (MCP) or a nucleic acid molecule encoding said MCP. Furthermore, the use of a MCP or a nucleic acid molecule encoding said MCP for the preparation of pharmaceutical compositions for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting tissue or cells with an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the attraction of monocytes. Described is further the use of an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through attraction of monocytes for the preparation of pharmaceutical compositions for the treatment of tumors.

14 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KOMC	Draw. Desc
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------------

 19. Document ID: US 6541224 B2

L6: Entry 19 of 29

File: USPT

Apr 1, 2003

US-PAT-NO: 6541224

DOCUMENT-IDENTIFIER: US 6541224 B2

**\*\* See image for Certificate of Correction \*\***

TITLE: Tumor necrosis factor delta polypeptides

DATE-ISSUED: April 1, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Germantown	MD		
Gentz; Reiner L.	Rockville	MD		
Dillon; Patrick J.	Carlsbad	CA		

US-CL-CURRENT: 435/69.5; 435/69.1, 435/69.7, 435/7.71, 435/70.1, 514/12, 514/2,  
530/350, 530/351

## ABSTRACT:

The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

50 Claims, 7 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 11

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Search](#) | [Print](#) | [Claims](#) | [HTMLC](#) | [Draw. Des.](#)

20. Document ID: US 6541008 B1

L6: Entry 20 of 29

File: USPT

Apr 1, 2003

US-PAT-NO: 6541008

DOCUMENT-IDENTIFIER: US 6541008 B1

TITLE: Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wise; Lyn M.	Dunedin			NZ
Mercer; Andrew A.	Dunedin			NZ
Savory; Loreen J.	Dunedin			NZ
Fleming; Stephen B.	Dunedin			NZ
Stacker; Steven A.	Parkville			AU

US-CL-CURRENT: 424/198.1; 514/2, 530/350

ABSTRACT:

The invention is based on the discovery that a viral VEGF-like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the VEGF receptor-2 to form bioactive complexes which mediate useful cellular responses and/or antagonize undesired biological activities. Disclosed are methods which stimulate or inhibit these biological activities, methods for therapeutic applications and antagonists of ORFV2-VEGF and/or NZ10.

17 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Search](#) | [Print](#) | [Claims](#) | [HTMLC](#) | [Draw. Des.](#)

21. Document ID: US 6521211 B1

L6: Entry 21 of 29

File: USPT

Feb 18, 2003

US-PAT-NO: 6521211

DOCUMENT-IDENTIFIER: US 6521211 B1

TITLE: Methods of imaging and treatment with targeted compositions

DATE-ISSUED: February 18, 2003

**INVENTOR-INFORMATION:**

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Wu; Yunqiu	Tucson	AZ		

US-CL-CURRENT: 424/9.52; 424/450, 424/9.5, 424/9.51, 514/18, 514/2, 600/431, 600/437**ABSTRACT:**

Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

58 Claims, 17 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	FIGMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-------	------------

 22. Document ID: US 6518236 B1

L6: Entry 22 of 29

File: USPT

Feb 11, 2003

US-PAT-NO: 6518236

DOCUMENT-IDENTIFIER: US 6518236 B1

TITLE: FGF homologs

DATE-ISSUED: February 11, 2003

**INVENTOR-INFORMATION:**

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deisher; Theresa A.	Seattle	WA		
Conklin; Darrell C.	Seattle	WA		
Raymond; Fenella	Seattle	WA		
Bukowski; Thomas R.	Seattle	WA		
Holderman; Susan D.	Seattle	WA		
Hansen; Birgit	Seattle	WA		
Sheppard; Paul O.	Redmond	WA		

US-CL-CURRENT: 514/2; 435/69.7, 514/12, 530/350, 530/399**ABSTRACT:**

The present invention relates to polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also

includes antibodies to the zFGF5 polypeptides.

5 Claims, 3 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 3

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMMC](#) | [Drawn Desc](#)

---

23. Document ID: US 6514935 B1

L6: Entry 23 of 29

File: USPT

Feb 4, 2003

US-PAT-NO: 6514935

DOCUMENT-IDENTIFIER: US 6514935 B1

TITLE: Methods of treating hypertension

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Mu-En	Newton	MA		
Yet; Shaw-Fang	Andover	MA		

US-CL-CURRENT: 514/2

ABSTRACT:

The invention features a method of inhibiting hypertension in a mammal by administering to the mammal a compound that reduces expression or activity of SmLIM.

3 Claims, 24 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Claims](#) | [KMMC](#) | [Drawn Desc](#)

---

24. Document ID: US 6498144 B1

L6: Entry 24 of 29

File: USPT

Dec 24, 2002

US-PAT-NO: 6498144

DOCUMENT-IDENTIFIER: US 6498144 B1

TITLE: Use of scatter factor to enhance angiogenesis

DATE-ISSUED: December 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Goldberg; Itzhak D.	Englewood	NJ		
Rosen; Eliot M.	Port Washington	NY		

## ABSTRACT:

This invention relates to a method of enhancing wound healing and to a method of enhancing organ transplantation utilizing scatter factor, either alone or in combination with a growth factor.

5 Claims, 39 Drawing figures  
 Exemplary Claim Number: 1  
 Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	TOINC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-------	------------

 25. Document ID: US 6475796 B1

L6: Entry 25 of 29

File: USPT

Nov 5, 2002

US-PAT-NO: 6475796

DOCUMENT-IDENTIFIER: US 6475796 B1

TITLE: Vascular endothelial growth factor variants

DATE-ISSUED: November 5, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pollitt; N. Stephen	Los Altos	CA		
Abraham; Judith A.	San Jose	CA		

US-CL-CURRENT: 435/455; 424/198.1, 514/2, 530/350

## ABSTRACT:

The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.

17 Claims, 17 Drawing figures  
 Exemplary Claim Number: 1  
 Number of Drawing Sheets: 17

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	TOINC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-------	------------

 26. Document ID: US 6440934 B1

L6: Entry 26 of 29

File: USPT

Aug 27, 2002

US-PAT-NO: 6440934

DOCUMENT-IDENTIFIER: US 6440934 B1

TITLE: Angiogenically effective unit dose of FGF-2 and method of use

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Whitehouse; Martha Jo	San Francisco	CA		

US-CL-CURRENT: 514/12; 424/423, 424/85.2, 424/94.4, 435/69.4, 514/2, 514/358,  
514/410, 514/411, 514/54, 514/56, 530/350, 530/380, 530/381, 530/383, 530/399,  
536/17.2, 536/21, 604/101.03

ABSTRACT:

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 .mu.g/kg to 48 .mu.g/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts six months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.

58 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Detailed Description](#) | [Claims](#) | [RQMC](#) | [Draw. Des.](#)

27. Document ID: US 6235713 B1

L6: Entry 27 of 29

File: USPT

May 22, 2001

US-PAT-NO: 6235713

DOCUMENT-IDENTIFIER: US 6235713 B1

TITLE: Vascular endothelial growth factor-D (VEGF-D) polypeptides

DATE-ISSUED: May 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Achen; Marc G.	Fitzroy			AU
Wilks; Andrew F.	South Yarra			AU
Stacker; Steven A.	North Fitzroy			AU
Alitalo; Kari	Espoo			FI

## ABSTRACT:

VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

16 Claims, 22 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	EMMC	Drawn Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

 28. Document ID: US 5932540 A

L6: Entry 28 of 29

File: USPT

Aug 3, 1999

US-PAT-NO: 5932540

DOCUMENT-IDENTIFIER: US 5932540 A

\*\* See image for Certificate of Correction \*\*

TITLE: Vascular endothelial growth factor 2

DATE-ISSUED: August 3, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hu; Jing-Shan	Sunnyvale	CA		
Rosen; Craig A.	Laytonsville	MD		
Cao; Liang	Hong Kong			HK

US-CL-CURRENT: 514/2; 530/326, 530/399, 530/402

## ABSTRACT:

Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

186 Claims, 22 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	EMMC	Drawn Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

29. Document ID: US 5824644 A

L6: Entry 29 of 29

File: USPT

Oct 20, 1998

US-PAT-NO: 5824644

DOCUMENT-IDENTIFIER: US 5824644 A

TITLE: Method of attenuating arterial stenosis

DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Abendschein; Dana R.	St. Louis	MO		

US-CL-CURRENT: 514/12; 424/422, 514/2, 514/21, 530/324, 530/350, 530/380

ABSTRACT:

A method is disclosed for attenuating stenosis after balloon angioplasty. The method comprises administering to a host parenterally or locally to the luminal surface of the blood vessel subjected to said balloon angioplasty an effective amount of tissue factor pathway inhibitor (TFPI) for a prolonged period of time sufficient to substantially reduce the extent of restenosis. An exemplary amount of the TFPI is from about 0.5 mg/kg to about 6 mg/kg during a prolonged administration of about twelve (12) hours to 36 hours.

14 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [KMD](#) | [Drawn Desc](#)

---

[Clear](#) | [Generate Collection](#) | [Print](#) | [Fwd Refs](#) | [Bkwd Refs](#) | [Generate OACs](#)

Terms	Documents
L5 AND L4	29

---

Display Format:  [Change Format](#)

[Previous Page](#)    [Next Page](#)    [Go to Doc#](#)

# Hit List

[Clear](#) | [Generate Collection](#) | [Print](#) | [Fwd Refs](#) | [Bkwd Refs](#) | [Generate DACS](#)

## Search Results - Record(s) 1 through 47 of 47 returned.

1. Document ID: US 20040176271 A1

**Using default format because multiple data bases are involved.**

L9: Entry 1 of 47

File: PGPB

Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040176271

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040176271 A1

TITLE: Compostions useful as inhibitors of JAK and other protein kinases

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bethiel, Randy S.	Lexington	MA	US	
Moon, Young-Choon	Belle Mead	NJ	US	

US-CL-CURRENT: 514/2

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KOMC](#) | [Drawn Des.](#)

2. Document ID: US 20040162232 A1

L9: Entry 2 of 47

File: PGPB

Aug 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040162232

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040162232 A1

TITLE: Elastin digest compositions and methods utilizing same

PUBLICATION-DATE: August 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mitts, Thomas	Visalia	CA	US	
Jimenez, Felipe	San Bernardino	CA	US	

US-CL-CURRENT: 514/2; 514/17, 514/19

ABSTRACT:

The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and

appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise epitopes of cytokines, growth factors and di-peptides. Methods of using these elastin digest comprising compositions for treating tissues in need of increased elasticity and or Elastin are described.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [EPOC](#) | [Draw. Des.](#)

---

3. Document ID: US 20040097401 A1

L9: Entry 3 of 47

File: PGPB

May 20, 2004

PGPUB-DOCUMENT-NUMBER: 20040097401

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040097401 A1

TITLE: Lysine in therapeutic angiogenesis, particularly in treating ischaemic conditions

PUBLICATION-DATE: May 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Datta, Debatosh	Kolkata		IN	

US-CL-CURRENT: 514/2; 514/564, 514/565

ABSTRACT:

Present invention features methods for induction of angiogenesis by administration of lysine (l-&d-) or lysine oligomers (molecular weight approx between 500 and 2500), both homo and hetero-oligomers, consisting of either l-or d- or both enantiomers.

Induction of Angiogenesis by the methods of the invention can be used in therapeutic angiogenesis, in, for example, treatment of ischaemic conditions and syndromes, such as chronic wounds (e.g diabetic wounds and ulcers, bed sores and other pressure sores, burns of various degrees and extents etc.) as well as coronary and cerebral ischaemia and peripheral vascular ischaemic conditions. Induction of angiogenesis by the described methods also will be useful in inducing/enhancing radiosensitivity in some solid tumors.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [EPOC](#) | [Draw. Des.](#)

---

4. Document ID: US 20030229007 A1

L9: Entry 4 of 47

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229007

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229007 A1

TITLE: Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Levi, Roberto	New York	NY	US	
Silver, Randi B.	New York	NY	US	

US-CL-CURRENT: 514/2; 424/146.1, 514/381

ABSTRACT:

The present invention provides a method for treating a human suffering from myocardial ischemia, cardiac arrhythmia, or both. The method comprises administering locally to a heart of a human an effective amount of an enzyme inhibitor that inhibits formation of angiotensin II in the heart. The invention also provides an isolated human renin of about 32-36 kDa.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMD](#) | [Draw. Des](#)

---

5. Document ID: US 20030215840 A1

L9: Entry 5 of 47

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215840

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030215840 A1

TITLE: Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas J.	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	
Galvin, Katherine M.	Jamaica Plain	MA	US	
Healy, Aileen	Medford	MA	US	
Acton, Susan L.	Lexington	MA	US	
Donoghue, Mary A.	West Roxbury	MA	US	
Stagliano, Nancy	North Reading	MA	US	
Perodin, Jacqueline	Arlington	MA	US	
Rodrigue-Way, Amelie	Malden	MA	US	

## ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 and 6585 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Reprint</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KIMC</a>	<a href="#">Draw. Des.</a>
----------------------	-----------------------	--------------------------	-----------------------	-------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	----------------------------

 6. Document ID: US 20030152574 A1

L9: Entry 6 of 47

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152574

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030152574 A1

TITLE: Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210

PUBLICATION-DATE: August 14, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas Joseph	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	

US-CL-CURRENT: 424/146.1; 435/7.2, 514/1, 514/2, 514/44

## ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1419, 58765 or 2210 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of

modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	WOINC	Drawn Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	------------

---

7. Document ID: US 20030125235 A1

L9: Entry 7 of 47

File: PGPB

Jul 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030125235

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030125235 A1

TITLE: Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases

PUBLICATION-DATE: July 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Foxwell, Brian Maurice John	Hammersmith		GB	

US-CL-CURRENT: 514/2; 435/7.2

ABSTRACT:

The present invention relates to a method of treating a condition comprising administering a pharmaceutically effective amount of an inhibitor of the Tec family of protein tyrosine kinases (PTKs). The condition is typically associated with cytokine production. Conditions addressed by the invention include sepsis, septic shock, inflammation, rheumatoid arthritis and Crohn's disease. In one embodiment, the condition is induced by zymosan. The invention also provides the use of an inhibitor of a member or members of the Tec family of PTKs in the manufacture of a medicament for use in the treatment of a condition associated with cytokine production and methods for identifying an inhibitor of a member or members of the Tec family of PTKs which is also suitable for use in the treatment of a condition associated with stimulus-induced cytokine production.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	WOINC	Drawn Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	------------

---

8. Document ID: US 20030119720 A1

L9: Entry 8 of 47

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119720

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030119720 A1

TITLE: Oligopeptide treatment of anthrax

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Khan, Nisar Ahmed	Rotterdam		NL	
Benner, Robert	Barendrecht		NL	

US-CL-CURRENT: 514/2

ABSTRACT:

The invention relates to the modulation of gene expression in a cell, also called gene control, in particular in relation to the treatment of anthrax. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signaling molecule comprising a peptide or functional analogue thereof.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [INMC](#) | [Draw. Des.](#)

9. Document ID: US 20030104977 A1

L9: Entry 9 of 47

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104977

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030104977 A1

TITLE: METHODS FOR INDUCING ANGIOGENESIS USING MORPHOGENIC PROTEINS AND STIMULATORY FACTORS

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
RIPAMONTI, UGO	SANDTON		ZA	
RAMOSHEBI, LENTSHA NATHANIEL	JOHANNESBURG		ZA	

US-CL-CURRENT: 514/2

ABSTRACT:

The present invention provides a method for inducing angiogenesis at a target locus in a mammal using morphogenic proteins. In addition, this invention also features a method for improving the angiogenic capability of a morphogenic protein at a target locus in a mammal. In this method, the morphogenic protein is capable of inducing angiogenesis when accessible to a progenitor cell in the mammal, and the morphogenic protein stimulatory factor enhances that capability. The morphogenic protein and morphogenic protein stimulatory factor can be administered simultaneously to the target locus. Alternatively, the two components are administered separately, in any order.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [INMC](#) | [Draw. Des.](#)

10. Document ID: US 20030083231 A1

L9: Entry 10 of 47

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030083231  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20030083231 A1

TITLE: Blood cell deficiency treatment method

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ahlem, Clarence N.	San Diego	CA	US	
Reading, Christopher	San Diego	CA	US	
Frincke, James	San Diego	CA	US	
Stickney, Dwight	Granite Bay	CA	US	
Lardy, Henry A.	Madison	WI	US	
Marwah, Padma	Middleton	WI	US	
Marwah, Ashok	Middleton	WI	US	
Prendergast, Patrick T.	Straffan		IE	

US-CL-CURRENT: 514/2; 514/169, 514/173, 514/26, 514/44, 514/63

ABSTRACT:

The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17- -one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost- -4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandros- tane that can be used in the treatment method.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Draw. Des.](#)

---

11. Document ID: US 20030082532 A1

L9: Entry 11 of 47

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082532  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20030082532 A1

TITLE: TUMOR NECROSIS FACTOR RECEPTOR RELATED GENE 12 POLYPEPTIDES

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
NI, JIAN	ROCKVILLE	MD	US	
RUBEN, STEVEN M.	OLNEY	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/7.2, 514/2, 530/350, 530/387.9,  
536/23.5

**ABSTRACT:**

The present invention relates to a novel human protein called TNFR Related Gene 12, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMD](#) | [Drawn Desc](#)

---

12. Document ID: US 20030022276 A1

L9: Entry 12 of 47

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022276

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030022276 A1

TITLE: DENDRITIC ENRICHED SECRETED LYMPHOCYTE ACTIVATION MOLECULE

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
YOUNG, PAUL	GAITHERSBURG	MD	US	
RUBEN, STEVEN M.	OLNEY	MD	US	

US-CL-CURRENT: 435/69.1; 424/130.1, 435/320.1, 435/325, 435/7.1, 514/2, 530/350,  
536/23.5

ABSTRACT:

The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMD](#) | [Drawn Desc](#)

---

13. Document ID: US 20020123091 A1

L9: Entry 13 of 47

File: PGPB

Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020123091

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020123091 A1

TITLE: Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization

PUBLICATION-DATE: September 5, 2002

**INVENTOR-INFORMATION:**

NAME	CITY	STATE	COUNTRY	RULE-47
Gurney, Austin L.	Belmont	CA	US	
Kirchhofer, Daniel K.	Los Altos	CA	US	
Wood, William I.	Hillsborough	CA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/7.21, 514/2, 514/44, 530/387.9,  
536/23.5

**ABSTRACT:**

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy.

In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Drawn Des.](#)

---

 **14. Document ID: US 20020061521 A1**

L9: Entry 14 of 47

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061521

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061521 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: May 23, 2002

**INVENTOR-INFORMATION:**

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1**ABSTRACT:**

The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided

encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [EPOC](#) | [Draw. Des.](#)

---

15. Document ID: US 20020058612 A1

L9: Entry 15 of 47

File: PGPB

May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058612

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Franco, Wayne P.

Rocky Hill

CT

US

US-CL-CURRENT: 514/2; 424/43

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [EPOC](#) | [Draw. Des.](#)

---

16. Document ID: US 20020037837 A1

L9: Entry 16 of 47

File: PGPB

Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037837

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020037837 A1

TITLE: Process for producing sustained-release preparation

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Takada, Shigeyuki	Hyogo		JP	
Taira, Keiko	Osaka		JP	
Iwasa, Susumu	Kyoto		JP	

US-CL-CURRENT: 514/2; 514/253.01, 514/254.01, 514/255.01

ABSTRACT:

The present invention is to provide sustained-release microcapsules which contains high amount of a drug, suppresses initial release and shows stable release, and the production method of which comprises adding a physiologically active substance to biodegradable polymer in an organic solvent containing a fat and oil (in particular, vitamin E) and dispersing and emulsifying the mixture.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [NOMC](#) | [Drawn Desq](#)

---

17. Document ID: US 20020037832 A1

L9: Entry 17 of 47

File: PGPB

Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037832

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020037832 A1

TITLE: Use of alpha-MSH and EPO for preventing or treating ischemic conditions

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nielsen, Soren	Abyhoj		DK	
Frokiaer, Jorgen	Abyhoj		DK	
Jonassen, Thomas Engelbrecht Norkild	Frederiksberg		DK	
Bjerke, Thorbjorn	Fredensborg		DK	

US-CL-CURRENT: 514/2; 514/169

ABSTRACT:

Alpha--melanocyte stimulating hormone (.alpha.-MSH) or an equivalent is used, in conjunction with erythropoietin (EPO) or equivalent, to prevent or treat ischemic conditions.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [NOMC](#) | [Drawn Desq](#)

18. Document ID: US 20020013261 A1

L9: Entry 18 of 47

File: PGPB

Jan 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020013261

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020013261 A1

TITLE: Methods and compositions for promoting angiogenesis using polyethylene glycol (PEG) polymers

PUBLICATION-DATE: January 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pawliuk, Robert	Medford	MA	US	
Leboulch, Philippe	Charlestown	MA	US	

US-CL-CURRENT: 514/2; 514/44, 514/54, 514/718

ABSTRACT:

Novel methods and compositions for stimulating angiogenesis, particularly at regions of myocardial and peripheral tissue ischemia are disclosed. Angiogenesis is promoted or enhanced by contacting a polyethylene glycol (PEG) polymer, such as a PEG mono-, di-, tri-, or tetraacrylate containing a photoinitiator (eosin Y) and a radical generator (triethanolamine) and a reaction accelerator (n-vinyl pyrrolidine), with an area of tissue ischemia. The PEG polymer can be applied alone or in conjunction with angiogenic proteins or genes encoding angiogenic proteins.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KOMC](#) | [Drawn Desc](#)

---

19. Document ID: US 20020006895 A1

L9: Entry 19 of 47

File: PGPB

Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006895

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006895 A1

TITLE: Method of treatment of cardiovascular injuries

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moulton, Karen S.	Weston	MA	US	
Folkman, Judah	Brookline	MA	US	

US-CL-CURRENT: 514/2; 424/85.6, 424/85.7, 514/326, 514/475

ABSTRACT:

The present invention provides a method for treating cardiovascular ailments. The method involves first screening an individual to determine their risk of having the

potential for unstable plaques. Such individuals can be selected by looking at one of the following criteria: (i) increased plaque neovascularization, (ii) area ratio of intima to wall area of a plaque, (iii) evidence of plaque hemorrhage, or (iv) inflammatory cells associated with plaque vessels. Looking at these criteria permits one to select individuals having the potential for unstable plaques. The method then involves treating the selected individual with an effective amount of an angiogenesis inhibitor.

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Draw. Des.](#)

---

20. Document ID: US 6800604 B2

L9: Entry 20 of 47

File: USPT

Oct 5, 2004

US-PAT-NO: 6800604

DOCUMENT-IDENTIFIER: US 6800604 B2

TITLE: Polypeptides that inhibit human serum-induced cleavage of hepatocyte growth factor

DATE-ISSUED: October 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gurney; Austin L.	Belmont	CA		
Kirchhofer; Daniel K.	Los Altos	CA		
Wood; William I.	Hillsborough	CA		

US-CL-CURRENT: 514/2; 424/198.1, 424/85.1, 514/12, 530/300, 530/350

ABSTRACT:

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cell comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

27 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Draw. Des.](#)

---

21. Document ID: US 6759386 B2

L9: Entry 21 of 47

File: USPT

Jul 6, 2004

US-PAT-NO: 6759386  
DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Rocky Hill	CT	06067	

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [EPOC](#) | [Draw. Des.](#)

---

22. Document ID: US 6723702 B2

L9: Entry 22 of 47

File: USPT

Apr 20, 2004

US-PAT-NO: 6723702

DOCUMENT-IDENTIFIER: US 6723702 B2

TITLE: Use of relaxin treat diseases related to vasoconstriction

DATE-ISSUED: April 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Conrad; Kirk P.	Cranberry Township	PA		
Lewis; Martyn	Menlo Park	CA		
Unemori; Elaine N.	Oakland	CA		
Huang; Xinfan	Menlo Park	CA		
Tozzi; Carol A.	Jackson	NJ		

US-CL-CURRENT: 514/12; 424/198.1, 514/2, 530/303, 604/19

ABSTRACT:

The invention related to methods of treating disease related to vasoconstriction that is a major factor in hypertensive vascular diseases and vasodilation, generally

comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is useful in treating a wide variety of diseases relating to vasoconstriction.

17 Claims, 28 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 15

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [HTML](#) | [Draw. Des.](#)

---

23. Document ID: US 6723347 B1

L9: Entry 23 of 47

File: USPT

Apr 20, 2004

US-PAT-NO: 6723347  
DOCUMENT-IDENTIFIER: US 6723347 B1

TITLE: Proces for producing protein powder

DATE-ISSUED: April 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yamagata; Yutaka	Kobe			JP
Doen; Takayuki	Suita			JP
Asakawa; Naoki	Takatsuki			JP
Takada; Shigeyuki	Nishimoniya			JP

US-CL-CURRENT: 424/489; 424/484, 514/2, 514/772.4, 514/964

ABSTRACT:

A process for conveniently producing a stable protein powder retaining the higher-order structure at a high level which comprises freezing a protein-containing solution at a cooling rate of about -300 to -10.degree. C./min. and then drying.

16 Claims, 1 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [HTML](#) | [Draw. Des.](#)

---

24. Document ID: US 6719977 B1

L9: Entry 24 of 47

File: USPT

Apr 13, 2004

US-PAT-NO: 6719977  
DOCUMENT-IDENTIFIER: US 6719977 B1  
\*\* See image for Certificate of Correction \*\*

TITLE: Methods to potentiate cancer therapies

DATE-ISSUED: April 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Seed; Brian	Boston	MA		
Jain; Rakesh K.	Boston	MA		

US-CL-CURRENT: 424/198.1; 424/85.5, 514/2, 530/303, 530/351

ABSTRACT:

Disclosed are methods for potentiating the anti-cancer properties of an anti-cancer therapy in a mammal by administering with the therapy a compound (such as relaxin or .gamma.-IFN) that has a tissue tensile modulus-reducing property, an ability to reduce the interstitial viscosity of the cancer, an ability to increase the hydraulic conductance of the cancer, or an ability to increase collagen turnover or decrease collagen formation at or near the cancer, where the therapy and the compound are administered at dosages which together are sufficient to destroy, slow, or arrest the cancer. Also disclosed is a method for treating cancer in a mammal involving the administration of relaxin and/or .gamma.-IFN peptides and an anti-cancer therapy to the mammal, where the peptides and the therapy are administered at dosages which together are sufficient to destroy, slow, or arrest the cancer.

8 Claims, 0 Drawing figures  
Exemplary Claim Number: 1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Detailed Description](#) | [Claims](#) | [RIMD](#) | [Draw. Des.](#)

---

25. Document ID: US 6706682 B2

L9: Entry 25 of 47

File: USPT

Mar 16, 2004

US-PAT-NO: 6706682

DOCUMENT-IDENTIFIER: US 6706682 B2

TITLE: Uses of vascular endothelial growth factor in the treatment of erectile dysfunction

DATE-ISSUED: March 16, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shabsigh; Ridwan	Wayne	NJ		

US-CL-CURRENT: 514/2; 514/12, 530/380

ABSTRACT:

This invention provides a method of increasing or maintaining the blood supply in the penis of a male subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's penis. This invention provides a method of treating erectile dysfunction in a subject which comprises-administering to the subject an amount of vascular endothelial growth factor effective to increase the blood supply in the subject's penis and thereby treat the subject's erectile dysfunction. This invention provides a method of increasing or maintaining the blood supply in the penis of a

subject which comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a suitable cell under conditions such that the nucleic acid expresses vascular endothelial growth factor so as to thereby increase or maintain the blood supply in the subject's penis. This invention provides a method of increasing or maintaining the blood supply in the genital area of a female subject which comprises administering to the subject an amount of vascular endothelial growth factor effective to increase or maintain the blood supply in the subject's genital area.

5 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RQNC	Dra. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

26. Document ID: US 6693077 B1

L9: Entry 26 of 47

File: USPT

Feb 17, 2004

US-PAT-NO: 6693077

DOCUMENT-IDENTIFIER: US 6693077 B1

TITLE: Keratinocyte growth factor-2

DATE-ISSUED: February 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruben; Steven M.	Brookeville	MD		
Jimenez; Pablo	Chatham	NJ		
Duan; D. Roxanne	Gaithersburg	MD		
Rampy; Mark A.	Montgomery Village	MD		
Mendrick; Donna	Mount Airy	MD		
Zhang; Jun	San Diego	CA		
NI; Jian	Germantown	MD		
Moore; Paul A.	North Bethesda	MD		
Coleman; Timothy A.	Gaithersburg	MD		
Gruber; Joachim R.	Dallas	TX		
Dillon; Patrick J.	Carlsbad	CA		
Gentz; Reiner L.	Belo Horizonte-Mg			BR

US-CL-CURRENT: 514/12; 514/2, 530/399

ABSTRACT:

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as "KGF-2" also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

48 Claims, 80 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 64

Full Title Citation Front Review Classification Date Reference Claims EPOC Draw. Des.

27. Document ID: US 6649591 B2

L9: Entry 27 of 47

File: USPT

Nov 18, 2003

US-PAT-NO: 6649591

DOCUMENT-IDENTIFIER: US 6649591 B2

**\*\* See image for Certificate of Correction \*\***

TITLE: Polydithiocarbamate-containing non-targeting macromolecules and the use thereof for therapeutic and diagnostic applications

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lai; Ching-San	Encinitas	CA		

US-CL-CURRENT: 514/6; 424/9.3, 424/9.34, 424/9.35, 514/2, 514/44, 514/476, 514/483,  
514/54, 530/403, 530/404, 530/405, 536/123, 536/123.1, 536/22.1

ABSTRACT:

In accordance with the present invention, there is provided a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. Thus, in accordance with the present invention, dithiocarbamates are linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein) either by using cross-linking reagents or by nonspecific binding to produce polydithiocarbamate-macromolecule-containing compositions, which represent a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. In accordance with another aspect of the present invention, combinational therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of NO synthase expression. In accordance with yet another aspect of the present invention, magnetic resonance imaging methods have been developed for the measurement of cerebral and cardiac blood flow and infarct volume in ischemic stroke or heart attack situations. Such methods employ iron-containing complexes of a composition comprising a dithiocarbamate and a non-immunogenic, non-targeting macromolecule other than an antibody as contrast agents.

18 Claims, 1 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 1

Full Title Citation Front Review Classification Date Reference Claims EPOC Draw. Des.

28. Document ID: US 6620784 B1

US-PAT-NO: 6620784  
 DOCUMENT-IDENTIFIER: US 6620784 B1

TITLE: Uses of VEGF-E

DATE-ISSUED: September 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ferrara; Napoleone	San Francisco	CA		
Kuo; Sophia S.	San Francisco	CA		

US-CL-CURRENT: 514/12; 514/2, 530/399

ABSTRACT:

The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.

5 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	RUMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

29. Document ID: US 6607740 B1

US-PAT-NO: 6607740

DOCUMENT-IDENTIFIER: US 6607740 B1

**\*\* See image for Certificate of Correction \*\***

TITLE: Enzyme-mediated modification of fibrin for tissue engineering

DATE-ISSUED: August 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hubbell; Jeffrey A.	Zumikon			CH
Schense; Jason	Zurich			CH

US-CL-CURRENT: 424/423; 435/193, 514/2, 530/300, 530/350, 530/402

ABSTRACT:

The invention provides fibrin-based, biocompatible materials useful in promoting cell growth, wound healing, and tissue regeneration. These materials are provided as part of several cell and tissue scaffolding structures that provide particular application

for use in wound-healing and tissue regenerating. Methods for preparing these compositions and using them are also disclosed as part of the invention. A variety of peptides may be used in conjunction with the practice of the invention, in particular, the peptide IKVAV, and variants thereof. Generally, the compositions may be described as comprising a protein network (e.g., fibrin) and a peptide having an amino acid sequence that comprises a transglutaminase substrate domain (e.g., a factor XIIIa substrate domain) and a bioactive factor (e.g., a peptide or protein, such as a polypeptide growth factor), the peptide being covalently bound to the protein network. Other applications of the technology include their use on implantable devices (e.g., vascular grafts), tissue and cell scaffolding. Other applications include use in surgical adhesive or sealant, as well as in peripheral nerve regeneration and angiogenesis.

18 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full Title Citation Front Review Classification Date Reference      Claims RQMC Draw. Des.

30. Document ID: US 6605592 B2

L9: Entry 30 of 47

File: USPT

Aug 12, 2003

US-PAT-NO: 6605592

DOCUMENT-IDENTIFIER: US 6605592 B2

TITLE: Protein HOFNF53

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Baker; Kevin P.	Darnestown	MD		
Birse; Charles E.	North Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Fiscella; Michele	Bethesda	MD		
Komatsoulis; George A.	Silver Spring	MD		
LaFleur; David W.	Washington	DC		
Moore; Paul A.	Germantown	MD		
Olsen; Henrik S.	Gaithersburg	MD		
Rosen; Craig A.	Laytonsville	MD		
Ruben; Steven M.	Olney	MD		
Soppet; Daniel R.	Centreville	VA		
Young; Paul E.	Gaithersburg	MD		
Wei; Ping	Brookville	MD		
Florence; Kimberly A.	Rockville	MD		

US-CL-CURRENT: 514/2; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1,  
435/71.1, 435/71.2, 514/12, 514/8, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic

acids containing the coding regions of the genes encoding such proteins. In particular, the present application relates to a novel human protein, Protein HOFNF53. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

19 Claims, 22 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 22

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [KIMC](#) | [Draw. Des.](#)

31. Document ID: US 6592862 B1

L9: Entry 31 of 47

File: USPT

Jul 15, 2003

US-PAT-NO: 6592862

DOCUMENT-IDENTIFIER: US 6592862 B1

TITLE: Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schaper; Wolfgang	Bad Nauheim/Rodgen			DE
Ito; Wulf D.	Luneburg			DE

US-CL-CURRENT: 424/85.1; 514/12, 514/2, 514/8

ABSTRACT:

Described is the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting tissue or cells with a monocyte chemotactic protein (MCP) or a nucleic acid molecule encoding said MCP. Furthermore, the use of a MCP or a nucleic acid molecule encoding said MCP for the preparation of pharmaceutical compositions for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting tissue or cells with an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the attraction of monocytes. Described is further the use of an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through attraction of monocytes for the preparation of pharmaceutical compositions for the treatment of tumors.

14 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [KIMC](#) | [Draw. Des.](#)

32. Document ID: US 6566325 B2

L9: Entry 32 of 47

File: USPT

May 20, 2003

US-PAT-NO: 6566325

DOCUMENT-IDENTIFIER: US 6566325 B2

TITLE: 49 human secreted proteins

DATE-ISSUED: May 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Moore; Paul A.	Germantown	MD		
Ruben; Steven M.	Olney	MD		
Olsen; Henrik S.	Gaithersburg	MD		
Shi; Yanggu	Gaithersburg	MD		
Rosen; Craig A.	Laytonsville	MD		
Florence; Kimberly A.	Rockville	MD		
Soppet; Daniel R.	Centreville	VA		
LaFleur; David W.	Washington	DC		
Endress; Gregory A.	Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Komatsoulis; George	Silver Spring	MD		
Duan; Roxanne D.	Bethesda	MD		

US-CL-CURRENT: 514/2; 530/300, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

52 Claims, 0 Drawing figures

Exemplary Claim Number: 1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [KOMC](#) | [Drawings](#)

33. Document ID: US 6541224 B2

L9: Entry 33 of 47

File: USPT

Apr 1, 2003

US-PAT-NO: 6541224

DOCUMENT-IDENTIFIER: US 6541224 B2

\*\* See image for Certificate of Correction \*\*

TITLE: Tumor necrosis factor delta polypeptides

DATE-ISSUED: April 1, 2003

**INVENTOR-INFORMATION:**

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Germantown	MD		
Gentz; Reiner L.	Rockville	MD		
Dillon; Patrick J.	Carlsbad	CA		

US-CL-CURRENT: 435/69.5; 435/69.1, 435/69.7, 435/7.71, 435/70.1, 514/12, 514/2,  
530/350, 530/351

**ABSTRACT:**

The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

50 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	EDOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------------

---

 34. Document ID: US 6537966 B1

L9: Entry 34 of 47

File: USPT

Mar 25, 2003

US-PAT-NO: 6537966

DOCUMENT-IDENTIFIER: US 6537966 B1

TITLE: Follistatin-3

DATE-ISSUED: March 25, 2003

**INVENTOR-INFORMATION:**

NAME	CITY	STATE	ZIP CODE	COUNTRY
Duan; D. Roxanne	Bethesda	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 514/2; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1,  
435/69.4, 435/71.1, 435/71.2, 514/12, 514/8, 530/350, 530/399, 530/402

**ABSTRACT:**

The present invention relates to a novel follistatin-3 protein which is a member of the family of inhibin-related proteins. In particular, isolated nucleic acid molecules are provided encoding the human follistatin-3 protein. Follistatin-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of follistatin-3 activity. Also provided are diagnostic methods for detecting reproductive system-related disorders and disorders of the regulation of cell growth and differentiation and therapeutic methods for treating reproductive system-related disorders and disorders of the regulation of cell growth and differentiation.

67 Claims, 5 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 5

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Detailed Abstract](#) | [Claims](#) | [KMMC](#) | [Drawn Desc.](#)

35. Document ID: US 6521211 B1

L9: Entry 35 of 47

File: USPT

Feb 18, 2003

US-PAT-NO: 6521211  
DOCUMENT-IDENTIFIER: US 6521211 B1

TITLE: Methods of imaging and treatment with targeted compositions

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Wu; Yunqiu	Tucson	AZ		

US-CL-CURRENT: 424/9.52; 424/450, 424/9.5, 424/9.51, 514/18, 514/2, 600/431, 600/437

ABSTRACT:

Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

58 Claims, 17 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 12

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Detailed Abstract](#) | [Claims](#) | [KMMC](#) | [Drawn Desc.](#)

36. Document ID: US 6518236 B1

L9: Entry 36 of 47

File: USPT

Feb 11, 2003

US-PAT-NO: 6518236  
DOCUMENT-IDENTIFIER: US 6518236 B1

TITLE: FGF homologs

DATE-ISSUED: February 11, 2003

**INVENTOR-INFORMATION:**

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deisher; Theresa A.	Seattle	WA		
Conklin; Darrell C.	Seattle	WA		
Raymond; Fenella	Seattle	WA		
Bukowski; Thomas R.	Seattle	WA		
Holderman; Susan D.	Seattle	WA		
Hansen; Birgit	Seattle	WA		
Sheppard; Paul O.	Redmond	WA		

US-CL-CURRENT: 514/2; 435/69.7, 514/12, 530/350, 530/399**ABSTRACT:**

The present invention relates to polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF5 polypeptides.

5 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KOMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------------

 37. Document ID: US 6514935 B1

L9: Entry 37 of 47

File: USPT

Feb 4, 2003

US-PAT-NO: 6514935

DOCUMENT-IDENTIFIER: US 6514935 B1

TITLE: Methods of treating hypertension

DATE-ISSUED: February 4, 2003

**INVENTOR-INFORMATION:**

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Mu-En	Newton	MA		
Yet; Shaw-Fang	Andover	MA		

US-CL-CURRENT: 514/2**ABSTRACT:**

The invention features a method of inhibiting hypertension in a mammal by administering to the mammal a compound that reduces expression or activity of SmLIM.

3 Claims, 24 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

38. Document ID: US 6498144 B1

L9: Entry 38 of 47

File: USPT

Dec 24, 2002

US-PAT-NO: 6498144

DOCUMENT-IDENTIFIER: US 6498144 B1

TITLE: Use of scatter factor to enhance angiogenesis

DATE-ISSUED: December 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Goldberg; Itzhak D.	Englewood	NJ		
Rosen; Eliot M.	Port Washington	NY		

US-CL-CURRENT: 514/12; 514/2, 530/324, 530/350, 530/399

ABSTRACT:

This invention relates to a method of enhancing wound healing and to a method of enhancing organ transplantation utilizing scatter factor, either alone or in combination with a growth factor.

5 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

39. Document ID: US 6440934 B1

L9: Entry 39 of 47

File: USPT

Aug 27, 2002

US-PAT-NO: 6440934

DOCUMENT-IDENTIFIER: US 6440934 B1

TITLE: Angiogenically effective unit dose of FGF-2 and method of use

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Whitehouse; Martha Jo	San Francisco	CA		

US-CL-CURRENT: 514/12; 424/423, 424/85.2, 424/94.4, 435/69.4, 514/2, 514/358,  
514/410, 514/411, 514/54, 514/56, 530/350, 530/380, 530/381, 530/383, 530/399,  
536/17.2, 536/21, 604/101.03

ABSTRACT:

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 .mu.g/kg to 48 .mu.g/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts six months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.

58 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [EPOC](#) | [Draw. Des.](#)

40. Document ID: US 6399078 B1

L9: Entry 40 of 47

File: USPT

Jun 4, 2002

US-PAT-NO: 6399078

DOCUMENT-IDENTIFIER: US 6399078 B1

**\*\* See image for Certificate of Correction \*\***

TITLE: Chemokine--glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases

DATE-ISSUED: June 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Devico; Anthony L.	Alexandria	VA		
Lewis; George K.	Baltimore	MD		
Burns; Jennifer M.	Baltimore	MD		
Gallo; Robert	Bethesda	MD		

US-CL-CURRENT: 424/278.1; 424/185.1, 424/279.1, 514/2, 514/56, 514/59, 514/885

ABSTRACT:

The present invention provides therapeutic compositions of receptor ligand-containing antagonist complexes and methods of using them to treat diseases, disorders or conditions associated with the function or aberrant function of a cell surface receptor.

24 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

41. Document ID: US 6391589 B1

L9: Entry 41 of 47

File: USPT

May 21, 2002

US-PAT-NO: 6391589

DOCUMENT-IDENTIFIER: US 6391589 B1

TITLE: Human chemokine beta-10 mutant polypeptides

DATE-ISSUED: May 21, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Olsen; Henrik S.	Gaithersburg	MD		
Li; Haodong	Gaithersburg	MD		
Adams; Mark D.	North Potomac	MD		
Gentz; Solange H. L.	Rockville	MD		
Alderson; Ralph	Gaithersburg	MD		
Li; Yuling	Germantown	MD		
Parmelee; David	Rockville	MD		
White; John R.	Coatsville	PA		
Appelbaum; Edward R.	Blue Bell	PA		

US-CL-CURRENT: 435/69.5; 424/85.1, 435/252.3, 435/254.11, 435/320.1, 435/325,  
435/471, 435/71.1, 435/71.2, 514/12, 514/2, 514/8, 530/324, 536/23.1, 536/23.5

## ABSTRACT:

Human chemokine Beta-10 polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.

50 Claims, 21 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 14

 42. Document ID: US 6331422 B1

L9: Entry 42 of 47

File: USPT

Dec 18, 2001

US-PAT-NO: 6331422

DOCUMENT-IDENTIFIER: US 6331422 B1

TITLE: Enzyme-mediated modification of fibrin for tissue engineering

DATE-ISSUED: December 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hubbell; Jeffrey A.	Zumiken			CH
Schense; Jason	Zurich			CH

US-CL-CURRENT: 435/193; 424/423, 514/2, 530/300, 530/350, 530/402

ABSTRACT:

The invention provides fibrin-based, biocompatible materials useful in promoting cell growth, wound healing, and tissue regeneration. These materials are provided as part of several cell and tissue scaffolding structures that provide particular application for use in wound-healing and tissue regenerating. Methods for preparing these compositions and using them are also disclosed as part of the invention. A variety of peptides may be used in conjunction with the practice of the invention, in particular, the peptide IKVAV, and variants thereof. Generally, the compositions may be described as comprising a protein network (e.g., fibrin) and a peptide having an amino acid sequence that comprises a transglutaminase substrate domain (e.g., a factor XIIIa substrate domain) and a bioactive factor (e.g., a peptide or protein, such as a polypeptide growth factor), the peptide being covalently bound to the protein network. Other applications of the technology include their use on implantable devices (e.g., vascular grafts), tissue and cell scaffolding. Other applications include use in surgical adhesive or sealant, as well as in peripheral nerve regeneration and angiogenesis.

39 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [KOMC](#) | [Draw. Des.](#)

---

43. Document ID: US 6329348 B1

L9: Entry 43 of 47

File: USPT

Dec 11, 2001

US-PAT-NO: 6329348

DOCUMENT-IDENTIFIER: US 6329348 B1

TITLE: Method of inducing angiogenesis

DATE-ISSUED: December 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Crystal; Ronald G.	Potomac	MD		
Rosengart; Todd K.	Highland Park	IL		

US-CL-CURRENT: 514/44; 435/320.1, 435/455, 435/456, 514/2, 530/350, 530/399

ABSTRACT:

The present invention provides a method for enhancing the level of perfusion of blood

<http://westbrs:9000/bin/gate.exe?f=TOC&state=7vm99q.10&ref=9&dbname=PGPB,USPT,U...> 10/15/04

to a target location in a host comprising establishing a gradient of an angiogenic mediator of increasing concentration from a source location (e.g., an angiogenically functional location) in the host to a target location (e.g., an angiogenically dysfunctional location) in the host, such that the level of perfusion of blood to the target location in the host is enhanced.

21 Claims, 0 Drawing figures  
Exemplary Claim Number: 1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [RQMC](#) | [Draw. Desc.](#)

---

44. Document ID: US 6303573 B1

L9: Entry 44 of 47

File: USPT

Oct 16, 2001

US-PAT-NO: 6303573

DOCUMENT-IDENTIFIER: US 6303573 B1

TITLE: Heart homing peptides and methods of using same

DATE-ISSUED: October 16, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruoslahti; Erkki	Rancho Santa Fe	CA		
MacKenna; Deidre A.	San Diego	CA		

US-CL-CURRENT: 514/12; 424/185.1, 514/14, 514/16, 514/2, 514/21, 530/300, 530/324,  
530/327, 530/328, 530/329

ABSTRACT:

The present invention provides a heart homing peptide that contains the amino acid sequence GGGVFWQ (SEQ ID NO: 2); HGRVRPH (SEQ ID NO: 3); VVLVTSS (SEQ ID NO: 4); CLHRGNSC (SEQ ID NO: 9); or CRSWNKADNRSC (SEQ ID NO: 10) and further provides conjugates in which a heart homing peptide is linked to a moiety such as a therapeutic agent. The conjugates of the invention are useful for treating cardiovascular diseases such as atherosclerosis and restenosis.

27 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [RQMC](#) | [Draw. Desc.](#)

---

45. Document ID: US 6287587 B1

L9: Entry 45 of 47

File: USPT

Sep 11, 2001

US-PAT-NO: 6287587

DOCUMENT-IDENTIFIER: US 6287587 B1

**\*\* See image for Certificate of Correction \*\***

TITLE: Process for producing sustained-release preparation by in-water drying

DATE-ISSUED: September 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shigeyuki; Takada	Hyogo			JP
Keiko; Taira	Osaka			JP
Susumu; Iwasa	Kyoto			JP

US-CL-CURRENT: 424/426; 424/451, 424/452, 424/457, 514/2, 514/937, 514/938, 514/962, 514/963

ABSTRACT:

The present invention is to provide sustained-release microcapsules which contains high amount of a drug, suppresses initial release and shows stable release, and the production method of which comprises adding a physiologically active substance to biodegradable polymer in an organic solvent containing a fat and oil (in particular, vitamin E) and dispersing and emulsifying the mixture.

14 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Abstract](#) | [Claims](#) | [EPOC](#) | [Drawn Desc](#)

---

46. Document ID: US 6056958 A

L9: Entry 46 of 47

File: USPT

May 2, 2000

US-PAT-NO: 6056958

DOCUMENT-IDENTIFIER: US 6056958 A

TITLE: Method of treatment of arterial and venous thromboembolic disorders

DATE-ISSUED: May 2, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mousa; Shaker Ahmed	Lincoln University	PA		

US-CL-CURRENT: 424/145.1; 424/130.1, 424/141.1, 514/2

ABSTRACT:

This invention relates to a method of prevention and/or treatment of thrombosis in a mammal without significantly altering bleeding time or coagulation. This invention further relates to methods of using selective inhibitors of the binding of vitronectin to the .alpha..sub.v .beta..sub.3 receptor, alone or in combination with other therapeutic agents, for the inhibition of thrombus formation and/or the treatment of thromboembolic disorders.

12 Claims, 0 Drawing figures

Exemplary Claim Number: 1

47. Document ID: US 5695761 A

L9: Entry 47 of 47

File: USPT

Dec 9, 1997

US-PAT-NO: 5695761

DOCUMENT-IDENTIFIER: US 5695761 A

TITLE: Suppression of nitric oxide production by osteopontin

DATE-ISSUED: December 9, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Denhardt; David T.	Bridgewater	NJ		
Hwang; Shiaw-Min	Piscataway	NJ		
Heck; Diane Elaine	Rumson	NJ		
Lopez; Cecilia Ang	North Brunswick	NJ		
Laskin; Debra L.	Basking Ridge	NJ		
Laskin; Jeffrey D.	Piscataway	NJ		

US-CL-CURRENT: 424/184.1; 424/278.1, 424/85.5, 514/12, 514/2, 530/300, 530/326,  
530/330, 530/351

ABSTRACT:

The present invention relates to compositions and methods for inhibition of the vasoactive and signal transduction agent nitric oxide (NO), and to therapeutic treatment of diseases or disorders that involve inappropriate or detrimental NO activity. The invention particularly relates to modulation of kidney function. In specific embodiments, osteopontin and a 20-amino acid fragment of osteopontin that contains an Arg-Gly-Asp sequence suppress expression of inducible NO synthase mRNA, and osteopontin suppresses the activity of constitutive NO synthase.

18 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

[Clear](#)

[Generate Collection](#)

[Print](#)

[Fwd Refs](#)

[Blwrd Refs](#)

[Generate OACS](#)

Terms	Documents
L7 AND L8	47

Display Format: [-] [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)